Spectrum Solutions Names Bill Phillips as New Chief Executive Officer
December 20, 2023
SALT LAKE CITY—December 18, 2023—Spectrum Solutions® and its owned corporations, Alimetrix, Inc., and Microarrays, Inc., today announced the appointment of Bill Phillips as the company’s new chief executive officer, replacing Stephen J. Fanning, who successfully served as Spectrum’s CEO for over four years.
Phillips was a founder of Spectrum Solutions and prior to his promotion to CEO, he served as the company’s Chief Operating Officer where he was recognized for his outstanding performance, strategic business acumen and strong leadership. In this new position, Phillips will accelerate Spectrum’s strategic clinical healthcare business objectives, which will result in job growth and greater career opportunities for current team members. In addition, Phillips is committed to working with other Utah business leaders to address issues impacting local businesses, philanthropic opportunities and the community at all levels.
“Bill Phillips’ promotion to CEO is well deserved and exciting for the future of Spectrum’s growth. Bill has worked tirelessly from the beginning to make Spectrum a customer-centric business and a great place for employees to come to work every day,” said Stephen Fanning. “It has been my privilege to work with such a great team of highly talented people, and it has been a highlight of my career.”
Phillips has received numerous national and local accolades and awards, including being named a 2020 Utah Business Healthcare Hero and recipient of BioUtah’s 2020 Life Science Innovation Impact Award. During the pandemic, his visionary leadership catapulted Spectrum to a global position in the battle against COVID-19 by offering the first FDA-authorized saliva-based diagnostic alternative to the painful nasal swab-based testing. Phillips directed the company’s expansion to meet new, global demands while scaling manufacturing capabilities. His visionary efforts launched a chain of events that led to several leading-edge scientific innovations and clinical tests that have vastly expanded the diagnostic options of saliva.
Recent News
- bioMérieux strengthens its next-generation sequencing capabilities with the acquisition of Day Zero Diagnostics solutions and technologies
- DGENTHERA AND NUSANO SIGN LETTER OF INTENT FOR ASTATINE‑211 SUPPLY
- 2025 BIO International Recap
- Halia Therapeutics Completes First-in-Human Phase 1 Study of HT-4253, a Novel LRRK2 Inhibitor Targeting Neuroinflammation
- Nelson Labs to Double Cleanroom Capacity to Support Growing Demand for Sterility Assurance Services
- RATIO THERAPEUTICS AND NUSANO ENTER LONG-TERM, MULTI-ISOTOPE SUPPLY AGREEMENT TO BOOST PRODUCTION OF CANCER RADIOPHARMACEUTICALS